Immutep ( (IMMP) ) has released its Q2 earnings. Here is a breakdown of the information Immutep presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Immutep Limited is a clinical stage biotechnology company focused on developing novel immunotherapies related to Lymphocyte Activation Gene-3 (LAG-3) for cancer and autoimmune diseases. In its latest half-year financial report, Immutep reported a 77% increase in total revenue and other income, reaching A$7.28 million, driven by higher interest and grant income. Despite this, the company experienced a 5% increase in net loss, totaling A$22.38 million, primarily due to increased research and development expenses. Key highlights include the advancement of its lead product candidate, eftilagimod alpha, into a Phase III trial for non-small cell lung cancer, and ongoing trials in head and neck squamous cell carcinoma and metastatic breast cancer. Immutep’s financial position remains strong with cash and short-term investments totaling A$159.26 million, providing a cash runway until the end of 2026. Looking forward, the company is poised to continue its clinical advancements and explore potential regulatory pathways for its therapies.